Concord Medical operates multidisciplinary cancer care in China, offering imaging diagnosis and radiotherapy plus cancer hospitals and independent medical institutions.
Concord Medical Services Holdings Limited files its **Form 20-F annual report** for the fiscal year ended **December 31, 2025**, with the U.S. Securities and Exchange Commission (SEC). The company, a China-based provider of cancer treatment, research, education, and prevention, submits the filing to disclose its financial performance and operational updates. The report is accessible via Concord Medical’s investor relations portal.
Concord Medical Services Holdings Limited announces its **2025 Annual Meeting of Shareholders** on **December 29, 2025**, at **10:00 a.m. Beijing Time**. The event will take place in **Room 26A1-26A5, East Tower, Hanwei Building, Beijing**, focusing on updates for shareholders of the cancer treatment and healthcare provider.
Concord Medical Services Holdings Limited releases its unaudited financial results for the first half of 2025. The company, a cancer treatment and research provider in China, reports performance metrics for the six-month period ending June 30, 2025. No specific revenue, profit, or operational details are disclosed in the announcement.
Concord Healthcare’s Guangzhou Concord Cancer Center performs China’s first proton therapy treatment for a patient with choroidal malignant melanoma. The procedure marks a milestone in advanced cancer treatment using proton beam therapy, a precision oncology technique. Concord Healthcare operates as a subsidiary of Concord Medical Services Holdings Limited, listed on the NYSE and HKSE.
Concord Medical updates its corporate governance by amending and replacing its Fourth Memorandum and Articles of Association during its 2024 annual general meeting. The Chinese healthcare provider, specializing in cancer treatment, research, education, and prevention, held the shareholder vote on December 27, 2024. Shareholders approved the changes via special resolution, reflecting updates to the company’s foundational documents.